Endocrinology

Sexual dysfunction in men was related to clinical factors, including erectile dysfunction, while women reported low emotional well-being and symptoms of anxiety.

Now that the agent shows benefit in mitigating comorbid risks, the expert advocates for more timely diagnoses and treatment initiation.

August's month in review features a pair of FDA approvals, new guidance on screening for gestational diabetes and T2D, a 3-part video series, and news on COVID-19, glucose control, and vitamin D levels.

Incidence of death from cardiovascular causes was lower in the finerenone group (458 of 3686 patients) compared to the placebo group (519 of 3666 patients).

Hailed by investigators as the largest and longest study of its kind, new research is providing clinicians with an overview of the potential for weight change and obesity among patients receiving gender-affirming hormone therapy.

The updated USPSTF recommends screening for prediabetes and type 2 diabetes in adults aged 35 - 75 years with conditions including overweight or obesity.

A recent study published in JAMA details increasing rates of gestational diabetes among first-time mothers in the US from 2011-2019, with rates increasing across all racial/ethnic subgroups examined in the 12 million person analysis.

A substudy of a prospective observational study performed at a hospital in Italy details potential associations of vitamin D levels with BMI and blood glucose and severity of COVID-19.

The treatment controls blood sugar levels after meals in adults with type 1 and type 2 diabetes.

An analysis of patients from a hospital in Belgium provides insight into the impact of COVID-19 and lockdowns on weight loss and overall health on patients who underwent gastric bypass and were impacted by COVID-19 during their first postoperative year.

Excessive hemolysis and genetic factors may be associated with cholelithiasis.

The latest recommendation statement reaffirms the USPSTF's 2014 guidance, which included a B recommendation for screening for gestational diabetes at 24 weeks of gestation or after.

Data show moderate net benefit for screening at 24 weeks of gestation or after, but there is insufficient evidence to assess benefit of screening before 24 weeks.

In an analysis, low GI/GL dietary patterns resulted in a reduction in HbA1c, compared with control diets with a mean difference of −0.31.

Patients with metabolic syndrome were at a 46% increased risk of a second stroke and a 27% increased risk of mortality when compared to their counterparts without metabolic syndrome.

An ancillary study to the INFINITE trial details the benefits of caloric restriction plus exercise versus exercise alone on aortic stiffness measured using CMRI in older adults with obesity.

Our latest emergency department case report from Brady Pregerson, MD, features a woman in her 60s with a history of diabetes presenting for post-menopausal vaginal bleeding. Can you determine the correct diagnosis?

The app will deliver up-to-the-minute glucose data in patients using Freestyle Libre 2 glucose sensors.

The FDA noted the extent of the treatment effect of tenapanor is of unclear clinical significance, despite evidence of efficacy.

Higher microbiome α diversity had an association with less T2D and lower insulin resistance in individuals without diabetes.

An analysis of a subset of patients from the STAMPEDE trial provides new evidence detailing the quality of life improvements associated with undergoing bariatric surgery in patients with uncontrolled type 2 diabetes.

Harold Bays, MD discussed the effectiveness of GLP-1 RA in treatment, as well as the development of oral semaglutide.

Analysis of more than 18 million pregnancies sheds light on the impact various prepregnancy cardiovascular risk factors, including BMI, smoking status, and diabetes, can have on risk of adverse maternal and fetal outcomes.

Using data from more than 2000 patients followed for 16 years, a Garvan Institute of Medical Research-led team found cognitive decline in older women could help predict bone loss and fracture risk among these patients.

Data show while women with GDM wanted to be responsible for their own health, an annual reminder and combined appointments would help to screen for T2D.

Data from a phase 2 study of women with overweight or obesity and polycystic ovary syndrome suggests use of licogliflozin was associated with significant reductions in hyperinsulinemia and androgenemia in this patient population.

A 12-week trial found implementing a dietary approach using a low-fat, vegan diet could help reduce the incidence of moderate-to-severe hot flashes in postmenopausal women.

Data show SGLT2is reduced HHF in patients with both stablished HFrEF and CKD and are likely to also be effective in patients with HFpEF.

FDA cites pharmacokinetic comparability considerations remained outstanding, while no clinical deficiencies on efficacy and safety were reported.